Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Vivos Therapeutics Inc (VVOS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$0.10-7.73%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for VVOS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Raise capital to support operations and growth | A supporting condition in Vivos Therapeutics Inc's published investment case. The stated target is Secure sufficient capital to fund operations through FY27. | Under Pressure | Fails to raise capital needed to continue operations | Qualitative: Nasdaq equity deficiency ($2.5M min) unresolved; $2.9M debt exchanged for stock Nasdaq deficiency notice for low equity; $2.9M debt exchanged for stock; Q2 revenue miss. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth and execution story, not yet a proven durable compounder, because the company remains loss-making and the evidence rates management execution as volatile. The long-term thesis is on watch: quarterly operating losses have narrowed, but positive cash flow has not been shown.
The valuation evidence describes VVOS as cheap versus peers, with low model confidence. The priced-in assessment says expectations are justified and fragility is low, though the sector regime is turbulent; the evidence does not give a more specific account of what the market assumes.
Near term, revenue was almost unchanged from the first to the second quarter of 2026, while operating losses narrowed. For the multi-year view, alliances and acquisitions of sleep healthcare providers are a stated growth priority, but distribution arrangements remain under negotiation and positive cash flow is not yet demonstrated. Recent misses, a 47% estimated miss probability, and possible guidance cuts make execution a key near-term risk.
The favorable case depends on expanding through provider alliances and acquisitions, improving margins and costs, and progressing toward positive cash flow. The unfavorable case includes weaker guidance or a weakening jobs trend, while continued strength from healthcare bellwethers could support the sector backdrop.
Over the next 1 to 3 years, VVOS remains an uncertain execution story: quarterly losses have improved, but revenue progress, cost control, and cash generation still need to be demonstrated. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Improve operating income and cash flow |
| A primary condition in Vivos Therapeutics Inc's published investment case. The stated target is Reduce operating losses toward -$2.8M or better. |
| Broken |
| Operating losses worsen beyond -$6.6M next year |
Operating income: $-4.825M FY2026-Q2; GAAP. Published target: Reduce operating losses toward -$2.8M or better. Target period is not explicitly aligned with this observation. Aug 14, 2026-4,825,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain Nasdaq listing by meeting price rules | A supporting condition in Vivos Therapeutics Inc's published investment case. The stated target is Stock price stays above Nasdaq minimum bid price. | Broken | Stock price falls below Nasdaq minimum bid price | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Sustain strong revenue growth | A primary condition in Vivos Therapeutics Inc's published investment case. The stated target is >=46.5% YoY revenue growth. | Improving | YoY revenue growth falls below 46.5% in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.79 → $-0.10 · observed estimates
$0.03B → $0.05B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-07-25 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-07-26 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-07-27 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-07-28 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-07-29 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-07-30 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-07-31 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-08-01 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-08-02 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-08-03 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-08-04 | $-0.79 | $34,089,000 | 3 / 3 |
| 2026-08-05 | $-0.79 | $34,089,000 | 3 / 3 |
| 2026-08-06 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-08-08 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-08-09 | $-0.79 | $34,089,000 | 3 / 3 |
| 2026-08-10 | $-0.79 | $34,089,000 | 3 / 3 |
| 2026-08-12 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-08-13 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-08-14 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-08-15 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-08-16 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-08-17 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-08-18 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-08-19 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-08-20 | $-0.79 | $34,089,000 | 2 / 2 |
| 2026-08-21 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-08-22 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-08-23 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-08-24 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-08-25 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-08-26 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-08-27 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-08-28 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-08-29 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-08-30 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-08-31 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-09-01 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-09-02 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-09-03 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-09-04 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-09-05 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-09-06 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-09-07 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-09-08 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-09-09 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-09-10 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-09-11 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-09-12 | $-0.82 | $34,087,333 | 2 / 2 |
| 2026-09-13 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-14 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-15 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-16 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-17 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-18 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-19 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-20 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-21 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-22 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-23 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-24 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-25 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-26 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-27 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-28 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-29 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-09-30 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-01 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-02 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-03 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-04 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-05 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-06 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-07 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-08 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-09 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-10 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-11 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-12 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-13 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-14 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-15 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-16 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-17 | $-0.15 | $38,881,000 | 2 / 2 |
| 2026-10-18 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-10-19 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-10-20 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-10-21 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-10-22 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-10-23 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-10-24 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-10-25 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-10-26 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-10-27 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-10-28 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-10-29 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-10-30 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-10-31 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-11-01 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-11-02 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-11-03 | $-0.10 | $45,075,000 | 2 / 2 |
| 2026-11-04 | $-0.10 | $45,075,000 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 18, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.